⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 8, 2024JHEP ReportsOpen Access

Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis

Hyun‐Jae Shin Won‐Mook Choi Seung Up Kim Yunmi Ko Youngsu Park Jeayeon Park Moon Haeng Hur Min Kyung Park Yun Bin Lee Yoon Jun Kim Jung‐Hwan Yoon Jeong‐Hoon Lee Fabien Zoulim

View Full Paper

Ask AI

Bookmark

Share

Abstract

The association between hepatitis B envelope antigen (HBeAg) seroclearance during long-term nucleos(t)ide analogue (NA) treatment and the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) remains unclear. Here, we aimed to investigate the association of HBeAg seroclearance during potent NA treatment with the development of HCC and decompensated cirrhosis.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shin et al. (2024) studied this question.

synapsesocial.com/papers/68e6fffcb6db64358767a214 https://doi.org/10.1016/j.jhepr.2024.101089

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1HBsAg seroclearance further reduces hepatocellular carcinoma but not hepatic decompensation in patients with cirrhosis and complete viral suppressionOriginal Research · 2026
2Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta‐analysisMeta-Analysis · 2021 · 63 citations
3Hepatocellular carcinoma surveillance after HBsAg seroclearance2024 · 2 citations
4The clinical significance and optimization strategies of HBeAg seroclearance in chronic hepatitis B treatmentReview · 2026
5Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research2024